Compare AbbVie Inc (ABBV) vs Akamai Technologies, Inc. (AKAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Akamai Technologies, Inc. — how do they compare? AbbVie Inc trades at $248.41 (market cap $441.94B), while Akamai Technologies, Inc. trades at $123.99 (market cap $16.77B). The key difference: AbbVie Inc is far larger — about 26.4× Akamai Technologies, Inc.'s market cap, and AbbVie Inc pays a 2.77% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | AKAM | |
|---|---|---|
Market Cap | $441.94B | $16.77B |
Sector | Health | Technology |
52-Week High | $263.58 | $161.14 |
52-Week Low | $197.38 | $71.97 |
Enterprise Value | $506.19B | $22.75B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Akamai Technologies (AKAM) trades at $117.65, up 6.43% on the day, buoyed by a recent analyst upgrade. The stock shows bearish technical signals but has beaten earnings estimates for three consecutive quarters, with Q2 2026 revenue growth of 5% year-over-year. Profit margins are under pressure due to increased infrastructure investments, though cloud and security demand remains strong.
The outlook is mixed: solid revenue growth and a consensus price target of $150.11 suggest upside, but margin compression and bearish technicals pose risks. Investors should weigh the company's strategic positioning in AI and cybersecurity against profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →
